HFDS® for modern MIGS surgery
In operative treatment of glaucoma, the mobile surgical platform CataRhex 3 allows for even greater safety and efficiency in micro-invasive glaucoma surgery (MIGS). HFDS creates direct access from the anterior chamber to the Schlemm’s canal, thereby avoiding the resistance of the trabecular meshwork. This leads to excellent long-term results and a low complication rate despite the short intervention time.
MAKING THE DIFFERENCE WITH UNIQUE ADVANTAGES
«HFDS offers three unique advantages in glaucoma surgery.
First, in about 70% of cases no postoperative treatment with medication is required. The second and biggest advantage in my opinion is that trabeculotomy and trabeculoplasty can be replaced by HFDS. Third, HFDS and phaco act additively and thus an IOP reduction of up to 13 mmHg can be achieved.»Dr. Gonzalo Murillo AzcarragaInstituto Privado de Oftalmología La Paz, Bolivia
MAKING THE DIFFERENCE WITH A MODERN GLAUCOMA METHOD
«Thanks to the modern HFDS method from Oertli, I am able to work quick and safe with little effort. It is also a good alternative to implants or filter surgery. The result speaks for itself - many patients are well regulated even after months without glaucoma drops.»PD Dr. med. Hans-Joachim HettlichAugen Praxisklinik Minden, Germany
MAKING THE DIFFERENCE WITH EXCELLENT LONG-TERM RESULTS
«HFDS convinces me because the procedure is very easy to perform, highly controllable and with few complications. Thanks to HFDS, excellent long-term results are achieved, resulting in fewer follow-up treatments for patients.»Dr. med., F.E.B.O. Lutz BlombergAugenzentrum Hildesheim-Alfeld, Germany
MAKING THE DIFFERENCE IN GLAUCOMA SURGERY
«For me, HFDS is an easy to apply MIGS solution, which convinces not only because of the fast rehabilitation post-op. High frequency diathermy is used to reduce the outflow resistance and shows excellent eye pressure reduction. HFDS can be excellently combined with cataract surgery.»Prof. Bojan PajicEye Clinic Orasis, Reinach, Switzerland
HFDS stands for High Frequency Deep Sclerotomy. In micro-invasive glaucoma surgery (MIGS), HFDS creates direct access from the anterior chamber to the Schlemm’s canal and further into the sclera. The resistance of the trabecular meshwork is thus bypassed. The HFDS glaucoma tip is inserted through 1.2 mm paracentesis and, by means of diathermy output, it creates six small sclerotomy pockets in the iridocorneal angle, ensuring improved outflow of aqueous fluid.
HFDS can be used individually and can also be ideally combined with cataract surgery. HFDS is characterised by a very short intervention time. Bleb formation is prevented, and so is fibroblast movement to the sclerotomy. Moreover, there are no corneal scars. Oertli’s High Frequency Deep Sclerotomy boasts excellent long-term results. If required, a further HFDS intervention can be made to optimise results.
Advantages of HFDS®
- Ideal in combination with cataract surgery or as individual application
- Very short intervention time
- Excellent long-term results
- No bleb-formation, no corneal scars
- Surgery can be repeated
- Very low complication rate
What is HFDS®?
HFDS (High Frequency Deep Sclerotomy) is the implant-free MIGS solution for glaucoma treatment. But what exactly is HFDS? This video explains in which cases the HFDS procedure is used and which instruments are applied.
The HFDS® procedure
The HFDS (High Frequency Deep Sclerotomy) procedure is an implant-free MIGS procedure to lower intraocular pressure by reducing the outflow resistance of the aqueous humour. In this animation, all surgical steps of the HFDS procedure are explained.
See HFDS® in application now
REDUCTION OF THE IOP
Clinical studies confirm a long-term significant reduction in the IOP with a considerable reduction in the number of antiglaucoma medication (AGM) . Together with the low complication rates, HFDS is a safe and efficient glaucoma procedure [1, 2, 3].
 B. Pajic, B. Pajic-Eggspuehler, and I. Haefliger, “New minimally invasive, deep sclerotomy ab-interno surgical procedure for glaucoma, six years of follow-up,” Journal of glaucoma, vol. 20, no. 2, pp. 109–114, 2011, doi: 10.1097/IJG.0b013e3181dddf31.
 B. Pajic, Z. Cvejic, K. Mansouri, M. Resan, and R. Allemann, “High-Frequency Deep Sclerotomy, A Minimal Invasive Ab-interno Glaucoma Procedure Combined with Cataract Surgery: Physical Properties and Clinical Outcome,” Applied Sciences, vol. 10, no. 1, p. 218, 2020, doi: 10.3390/app10010218.
 Kaweh Mansouri, M.D., M.P.H., A Multicenter Prospective Study of High-Frequency Deep Sclerotomy (HFDS) in Open-Angle Glaucoma: 3-Year Outcomes: Manuskript; UNPUBLISHED DATA.
Recent studies & postoperative treatment
With HFDS, a reduction in intraocular pressure is already noticeable in the first few days after the operation. In the following video you will learn why you do not need pressure-reducing eye drops and how the reduction in intraocular pressure is measured using the latest studies.
What do experts say about HFDS®?
You want to know more?
High Frequency Deep Sclerotomy, Dr Florian Sutter, Ophthalmology Times Europe, 2022
Triggerfish Recording of IOP Patterns in Combined HFDS Minimally Invasive Glaucoma and Cataract Surgery, Journal of Clinical Medicine, 2021
Ab Interno Approach with No Implant Needed, The Ophthalmologist, 2021
High-Frequency Deep Sclerotomy, A Minimal Invasive Ab Interno Glaucoma Procedure Combined with Cataract Surgery: Physical Properties and Clinical Outcome, Eye Clinic Orasis, 2019
The Efficacy and Safety of High-Frequency Deep Sclerotomy in Treatment of Chronic Open-Angle Glaucoma Patients, Research Institute of Ophthalmology Cairo, Cairo University Faculty of Medicine, 2019
Ab-Interno Deep Sclerotomy in Eight Simple Steps, Cataract & Refractive Surgery Today Europe, 2017
HFDS Glaucoma Procedure, Dr. Bojan Pajic, European Opthalmic Review, 2012
New Minimally Invasive, Deep Sclerotomy ab interno Surgical Procedure for Glaucoma, Six Years of Follow-up, Dr. Bojan Pajic, Journal of Glaucoma, 2011
The Future Way of Phaco & MIGS Surgeries - Highlights from ESCRS Satellite Symposium, The Ophthalmologist, 2015